EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective

There is a need for effective medications to treat patients living with schizophrenia or bipolar I disorder (BD-I). LYBALVI®, combination of olanzapine and samidorphan, was recently approved the treatment adults BD-I. We estimated budgetary impact adding LYBALVI formulary from Commercial, Medicaid, Medicare perspectives in United States (US). A budget model (BIM) 3-year time horizon developed hypothetical plans, each 1 million adult covered-lives. The BIM used prevalence-based approach estimate number BD-I treated atypical antipsychotics. Other inputs included projected market shares antipsychotics, average months on prescribed drug-acquisition costs based published information. assumed displace share other branded oral by comparing two scenarios: one without as option vs. an formulary. Results are presented differences per-member-per-month (PMPM) between these scenarios. After applying assumptions, numbers antipsychotics per covered lives were 4,324, 39,770, 12,178 year respectively. had net neutral no changes PMPM payer plan three years. In plans US, have additional plans’ budgets. offers new chronic serious mental health conditions, cost.